WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Goldman Sachs Thirty-Seventh Annual Global Healthcare Conference on June 7, 2016 at 3:20 p.m. PDT at the Terranea Resort in Rancho Palos Verdes, California.

The Company's presentation will be webcast live on the Company's website at www.radiuspharm.com, and a replay and presentation materials will also be available for a limited time.

About Radius Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe, and a New Drug Application (NDA) has been accepted for filing by the FDA.  The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer.
Investor Relations Contact:Barbara RyanEmail: bryan@radiuspharm.comPhone: 203-274-2825Media Contact:Lori GorskiEmail: lgorski@radiuspharm.comPhone: 617-551-4096